To view the graphs and study in PDF form please click here. 

Michael D. Farley, N.D.
225 Fifth Avenue, Suite #6, Indialantic, Florida 32903
Phone 407-728-4887 - Fax 407-728-4998
These are my preliminary findings and explanations of Trans-D Tropin.
As you are aware, human growth hormone (hGH) has been shown to have many beneficial effects
such as:

Decrease in body fat
• Increase in lean muscle mass
• Increase in sexual vigor
• Increase in energy
• Healing of old injuries
• Inhibition of some auto-immune diseases
• Increase in strength
• Improved sleep patterns
• Relief from symptoms of depression
• Increased immune system responses

Normal hGH secretions occur several times during a 24-hour day. During the initial stages of
falling asleep, hGH may increase as much as 200-300%. These normal pulsatile secretions allow
the body to take full advantage of the secreted hGH without causing dramatic increases of
somatostatin, the antagonist of growth hormone.
As the body ages, though still pulsatile in nature, the surges of hGH decline. These declining
levels occur very early in life, after complete height is reached or shortly thereafter. These
secretion levels diminish further with our aging. Other contributing factors include general
physical condition, activity level and diet.
Anti-aging medicine has embraced hGH injections as the Fountain of Youth, however hGH
injections have many drawbacks:

1. HGH is costly, usually between $700 and $1200 per month.
2. HGH injections inhibit the function of our own pituitary gland, as well as that of the
hypothalamus and adrenal gland. No long-term studies have been done to establish if normal
function ever returns.
3. Because of the inhibition of the pituitary gland, other hormone balances are disrupted. Often
cortisone must be used in conjunction with hGH due to the fact that hGH injections inhibit
ACTH secretion.
4. HGH injections increase IGF-1 (Insulin-like growth factor) levels. Increased IGF-1 levels
have been linked to increased rates of growth in both prostate and breast cancer cells.
Trans-D Tropin is an analogue of Growth Hormone Releasing Hormone (GHRH) that stimulates
the pituitary to produce and release more of our own HGH. In other words, it stimulates our own
body’s production of Human Growth Hormone in a pulsatile manner at every application time
during the day.
This increase in endogenous HGH during the normal 24-hour cycle offers many benefits over
conventional introduction of injected HGH, such as:

2
• Stimulation of our own pituitary gland, rather than its suppression, should in time increase its
vigor, and preliminary blood work has supported this. This should mean continuing increases
in the overall general health of the endocrine system. Injected hGH has exactly the opposite
effect, by supplying synthetic hGH, the hypothalamus-pituitary-adrenal axis is effectively
inhibited, and no long term studies on adults have been conducted to discover its long-term
effects.
• Much less costly, $175 retail per month, vs. $700-1200 per month for injectable is a
difference, which places this product in the realm of the general public.
• More normal hGH release in a pulsatile manner decreases somatostatin response, therefore
allowing hGH serum levels to remain elevated for 2 hours or more per application.
• Tests have shown consistent decreases in IGF-1 levels using Trans-D Tropin rather than
increases as seen with injectable hGH. This may decrease the likelihood of increasing cancer
growth in some types of cancer.
• Ease of application is greater with topical lotion vs. injection, meaning the applications may be
done at home or on the road at any time.
• Unlike injectable hGH, there are no allergic reactions to ones own hGH secreted from ones
own pituitary, making this product virtually side effect free.

When evaluating HGH secretagogues, several parameters are measured, which include HGH,
Somatomedin-C (IGF-1), and glucose levels. This is done at the highest normal dosage level, and
is measured against baseline blood levels. This enables us to measure changes, which occur over
a period of time. The following graphs and data are my findings to date on Trans-D Tropin. I
will also discuss my findings and compare them to similar research I have done with other
secretagogues and hGH sprays.

See PDF

This chart shows the rise of serum hGH levels by an average of well over 600% from baseline.
This is an increase of over 3 NG/ML of endogenous hGH. These tests have been repeated on 28
subjects for over 90 days, and the test results show an average improvement in pituitary response.

3
As a comparison, 2,3-butyrolactone (Renewtrient) gave an average HGH increase peak at 60
minutes at a value of 4.2 NG/ML, but had dropped to an average peak of only 2.38 MG/ML at 60
minutes within 25 days of continued use. 1,4-butanediol (SomatoPro) gave an average HGH
increase peak at 60 minutes at a value of 9.36 NG/ML, but had dropped to an average peak of
only 2.1 MG/ML at 60 minutes within 25 days of continued use. This demonstrates that
consistent use of these secretagogues actually decreases the pituitary’s response to them, while
the hGHRH analogue actually enhances the pituitary response over time.
Another research finding of 1,4-butanediol and 2,3-butyrolactone is that this major increase in
HGH release was done at the average sleep dose of 25 mg/kg. This may only be used once daily,
at bedtime. For a more normal, pulsatile release of HGH, Trans-D Tropin is applied three times
daily. This much more closely mimics our own normal biorhythm release of HGH. The
cumulative response of an average 3 NG/ML increase in endogenous HGH, three times daily, far
exceeds the once daily initial response of Renewtrient or SomatoPro. This is true, even in the
highest response period of their use, the first twenty days.
We have also tested a few of the oral HGH sprays which sell from anywhere between $75.00-
$125.00, including Biotropin G TA-5 and HGH Gold oral sprays. None of them increased serum
hGH levels at all. As a matter of fact, none of the oral sprays changed any of the parameters we
were measuring in any consistent manner whatsoever.
With Trans-D Tropin, average glucose levels dropped from 116.574 to 103.5 MG/DL during the
90-minute test period. This however is a small part of the glucose story. Glucose levels with
Trans-D Tropin seemed to drop for those with high serum glucose levels.

See PDF

On the other hand, it tended to rise with those glucose levels in the mid 70 MG/DL regions.

See PDF

Though the overall averages for glucose levels tended to drop from baseline to 90 minutes, I
believe it is evident that there tends to be a glucose modulating effect taking place with Trans-D
Tropin.

See PDF

Frequently IGF-1 levels are used to prove the efficacy of HGH secretagogues. Recent research
findings have shown this to be incorrect. The use of IGF-1 levels to measure current hGH levels
is equally erroneous. As can be easily seen from the graph, IGF-1 levels have dropped as HGH
levels increased.

In the initial research on Trans-D Tropin, overall IGF-1 levels dropped over a 30-day period,
which coincides with the immediate drops during our testing.

See PDF

Testing showed an average 19.81 NG/ML drop in serum IGF-1 levels within 90 minutes of
application during our testing. Baseline IGF-1 levels have fallen over the 60 days testing as well.

See PDF

An interesting note is that with 2,3-butyrolactone (Renewtrient) and 1,4-butanediol (SomatoPro)
IGF-1 levels fell as well. Not only do the IGF-1 levels fall as HGH levels rise, but over the long
term, they tend to decrease as well.
This data is important for at least two reasons. The first reason is that IGF-1 has been linked to
increasing rates of growth in several types of cancer, including prostate and breast. The second

6
reason is that many products and medical decisions are being made concerning HGH secretion
and levels using IGF-1 levels.
We have seen in this research that IGF-1 levels do not rise with elevated HGH secretion. On the
other, hand, Inukai T, et al, has found that thyroid hormone modulates insulin-like growth factor-
I(IGF-1) and IGF-binding protein-3, without mediation by growth hormone in patients with
autoimmune thyroid disease.{} Janssen YJ, et al has found a direct relationship between serum
levels of estradiol and IGF-1 levels, independent of HGH levels. There is a growing consensus
that IGF-1 levels are not a reliable indicator of HGH levels.{}
At this time, after over 90 days of testing, I feel that Trans-D Tropin is the safest and most
effective method of raising endogenous hGH levels available.
Current Contraindications for Trans-D Tropin:

• Active cancer of any type
• Pituitary adenoma
• Concurrent use of HGH injections
• Children and Young Adults who have not achieved full height and growth

In order to insure that a pituitary adenoma is not present, it is strongly recommended that
either a Somatomedin-C or Prolactin level be taken through a blood test.

1. Thyroid hormone modulates insulin-like growth factor-1(IGF-1) and IGF-binding protein-
3, without mediation by growth hormone, in patients with autoimmune thyroid disease.
Inuki T, Takanashi K, Takebayashi K, Fuiwara Y, Tayama K, Takemura Y
Horm Metab Res 1999 Oct;31 (10):576-9
2. A switch from oral (2 mg/day) to transdermal (50 micro/day) 17beta-estradiol therapy
increases serum insulin-like growth factor-I levels in recombinant human growth hormone
(GH)-substituted women with GH deficiency.

Janssen YJ, Helmerhorst F, Frolich M, Roelfsema F
J Clin Endocrinol Metab 2000
Jan;85(1):464-7
SmithKline Beecham Clinical Laboratories did all lab analysis on all samples.